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cognitive decline carrying one or two APOE4 alleles, and 
from that related to traumatic brain injury. Our novel find-
ings of Aβ deposits in the dura mater, including the grafted 
dura, and the distinct cerebral Aβ distribution in iCJD sup-
port the seeding properties of Aβ. However, in contrast to 
prion diseases, our study suggests that such Aβ seeding is 
unable to reproduce the full clinicopathological phenotype 
of AD.
Keywords Alzheimer disease · Amyloid-β · Dura mater · 
Iatrogenic Creutzfeldt-Jakob disease · Prion · Propagon
Introduction
Neurodegenerative diseases are characterized by progres-
sive loss of neurons and dysfunction of functional systems 
associated with deposition of pathological forms of proteins 
predominantly in the central nervous system [31]. These 
proteins, such as amyloid-β (Aβ), tau, α-synuclein, TAR 
DNA-binding protein TDP-43 or prion protein (PrP) can be 
used as biomarkers. However, a further important aspect is 
whether these proteins are capable of transmitting disease 
between individuals, which would have significant public 
health implications. This issue has received support from 
experimental observations; furthermore, the hierarchical 
involvement of anatomical regions, considered as phases or 
stages of disease, has been also considered to support the 
prion-like spread of disease-associated proteins [9, 15, 21, 
37, 55, 56]. Indeed, prion diseases are still the only protein 
misfolding disorders where human- or animal-to-human 
transmission has been proven. To fine-tune the terminology, 
recently the term propagon has been introduced and at least 
four conceptual levels have been defined, such as molec-
ular, tissue, systemic and infectious propagons [15]. As 
Abstract Deposition of amyloid-β (Aβ) in the brain 
parenchyma and vessels is one of the hallmarks of Alzhei-
mer disease (AD). Recent observations of Aβ deposition 
in iatrogenic Creutzfeldt-Jakob disease (iCJD) after dural 
grafting or treatment with pituitary extracts raised concerns 
whether Aβ is capable of transmitting disease as seen in 
prion diseases by the disease-associated prion protein. To 
address this issue, we re-sampled and re-evaluated archi-
val material, including the grafted dura mater of two cases 
with iCJD (28 and 33-years-old) without mutations in the 
AβPP, PSEN1 and PSEN2 genes, and carrying ε3/ε3 alleles 
of the APOE gene. In addition, we evaluated 84 dura mater 
samples obtained at autopsy (mean age 84.9 ± 0.3) in the 
community-based VITA study for the presence of Aβ depo-
sition. We show that the dura mater may harbor Aβ depos-
its (13 %) in the form of cerebral amyloid angiopathy or 
amorphous aggregates. In both iCJD cases, the grafted dura 
mater had accumulated Aβ. The morphology and distribu-
tion pattern of cerebral Aβ deposition together with the 
lack of tau pathology distinguishes the Aβ proteinopathy in 
iCJD from AD, from that seen in young individuals without 
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suggested, only prion diseases fulfill all four levels, while 
this has not yet been shown convincingly for other neuro-
degeneration-related proteins [15, 37, 55]. However, recent 
reports showed that iatrogenic Creutzfeldt-Jakob disease 
(iCJD) due to cadaveric pituitary hormones [25] or dura 
mater implantation [18, 46] frequently associates with Aβ 
deposition, suggesting that Aβ acts as a seed or infectious 
propagon as defined recently [15]. However, these studies 
did not evaluate the original source material nor focused on 
distinctive neuropathological features of these cases.
Aβ deposition is one important component of neuro-
pathological alterations that together with the accumulation 
of abnormally phosphorylated intracellular tau allows the 
tissue diagnosis of Alzheimer disease (AD) [14]. In con-
trast to prion diseases, AD is characterized by slowly pro-
gressive cognitive decline. Importantly, Aβ shows on one 
hand a maturation process [42] and on the other hand a 
hierarchical involvement of brain regions [53]. Moreover, 
two distinct patterns of neocortical involvement have been 
suggested, namely a homogenous distribution in all lay-
ers or a laminar pattern [12]. Cerebral amyloid angiopathy 
(CAA) with Aβ immunoreactivity is a frequent observation 
in the ageing and AD brains, which is thought to be related 
to failure of the interstitial fluid drainage of the brain [5, 
10]. Two types of CAA are distinguished and three stages 
of brain involvement have been proposed [51, 52].
Importantly, Aβ plaques can be observed in young indi-
viduals associated with the presence of the ε4 allele of the 
apolipoprotein E (APOE) gene [45]. On the other hand 
neuronal phospho-tau pathology can be seen in subcortical 
nuclei from the second decade of life and precedes cortical 
involvement [7, 8, 20, 50]. Furthermore, accelerated neuro-
degeneration has been reported after traumatic brain injury 
(TBI) either after single or, as chronic traumatic encepha-
lopathy (CTE), following repetitive brain trauma [27, 28, 
40, 41]. Aβ deposits together with tau-positive neurofibril-
lary tangles reminiscent of AD are seen already after single 
TBI [28], while in CTE, tau pathology with stages of brain 
involvement is the major finding, which is associated with 
deposition of further neurodegeneration-related proteins, 
including Aβ [39–41].
In the present study we were thus interested to clarify 
whether (1) the pattern of Aβ deposition in iCJD following 
cadaveric dura mater implantation would be distinguisha-
ble from that seen in AD, in cognitively normal young indi-
viduals, or in TBI; (2) the dural grafts in iCJD cases would 
show Aβ deposition; and (3) the dura mater would accu-
mulate Aβ in non-CJD cases. To answer these questions 
we re-sampled and carefully re-evaluated archival material, 
including the grafted dura mater of two cases with iCJD. In 
addition, we systematically evaluated dura mater samples 
collected in the community-based Vienna Trans-Danube 
Aging (VITA) study for the presence of Aβ deposition.
Materials and methods
Acquisition of cases
Two cohorts were examined in this study. The first cohort 
consisted of two autopsy cases of iCJD collected in the 
frame of the Austrian Surveillance for human prion dis-
eases. Both patients underwent dura mater transplan-
tation: case iCJD-1 was a 33-year-old female patient, 
and iCJD-2 was a 28-year-old male patient. The latter 
case was reported previously [46]. We re-evaluated both 
cases carefully and sampled further anatomical areas 
including the implanted and host dura mater. The sec-
ond cohort consisted of 84 consecutive dura mater sam-
ples collected in the frame of the community-based VITA 
study [16, 34]. The mean age at death (±standard error) 
of individuals in the VITA cohort was 84.9 ± 0.3 (range 
79–89 years); male/female ratio was 33/51). The study 
was performed following local regulations as approved by 
the local ethical committee (EK07-056-VK, 206/05/2008, 
EK396-2011).
Neuropathology
Formalin-fixed, paraffin-embedded tissue blocks were eval-
uated. Tissue blocks examined in iCJD cases comprised 
bilateral samples of the frontal (frontobasal area of trau-
matic surgery and dorsolateral), anterior cingular, lower, 
middle and upper temporal, parietal, and occipital cortices 
with white matter, hippocampus, entorhinal cortex, basal 
ganglia, thalamus, mesencephalon, pons, medulla oblon-
gata, and cerebellum. In case iCJD-1 we evaluated the 
implanted and immediately adjacent host dura mater. In 
case iCJD-2 the whole dura mater was available; thus we 
evaluated samples from the implanted areas and from those 
parts of the dura mater not involved in the traumatic injury 
(host dura, at least 5 cm distance from the surgical inter-
vention from both sides).
In the VITA cohort we sampled the left temporal region 
of the dura mater including branches of the middle menin-
geal artery (2 × 2 cm) as well as three cross-sections in the 
area of the superior sagittal sinus and confluence of sinuses. 
In addition to Hematoxylin and Eosin (HE), Congo red, 
van Gieson elastica, and Bielschowsky stainings, the fol-
lowing monoclonal antibodies were used for immunohis-
tochemistry: anti-PrP (1:1000, 12F10, Cayman Chemical, 
Ann Arbor, MI, USA), anti-Aβ (1:100, clone 6F/3D, Dako, 
Glostrup, Denmark), anti-Aβ (1:4000, clone 4G8, Signet, 
San Diego, CA, USA), anti-Aβ1-40 (1:800, clone 139-5, 
Signet, San Diego, CA USA), anti-Aβ1–42 (1:200, clone 
1-11-3, Signet, San Diego, CA USA), anti-AβPP (1:8000, 
clone 22C11, Millipore, Temecula, CA, USA), anti-phos-
pho-tau (1:200, clone AT8, Pierce Endogen, Waltham, MA, 
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USA), smooth muscle actin (1:200, clone HHF35, Dako, 
Glostrup, Denmark), anti-ubiquitin (1:50,000, Millipore, 
Temecula, CA, USA), anti-HLA-DR (1:100, clone CR3/43, 
Dako), anti-CD-68 (1:5000, clone KP1, Dako), and colla-
gen IV (1:100, clone CIV22, Dako, Glostrup, Denmark; to 
label basement membrane). The following tissue pretreat-
ments were used for the Aβ antibodies prior to incubation 
with primary antibodies: for 6F/3D and 4G8 1 h 80 % 
formic acid (FA); for anti-Aβ1–40 and anti-Aβ1–42 10 min 
70 % FA, for AT8 no pretreatment. Additional enhanced 
Proteinase K (PK) treatment (50 μg/ml) was used for 
6F/3D and 4G8 for 5 min at 37°C to test for PK resistance 
of the detected dural Aβ deposits. The Dako EnVision™ 
FLEX + Mouse / Rabbit detection system (Dako, Glostrup, 
Denmark) was used for visualization of antibody reactions.
In the VITA cohort we correlated the presence of dif-
ferent Aβ deposits in the dura with neuropathological 
variables, including presence and phase of Aβ deposi-
tion, presence and type of CAA, stages of neurofibrillary 
degeneration, presence of Lewy body, TDP-43 and vascular 
pathology (see Ref. [34]). Chi square test and Fisher’s exact 
test were used to evaluate association between variables of 
interest. IBM SPSS Statistics Version 20 was used for sta-
tistical analysis. A significance level of 0.05 was used.
Gene analysis
Genomic DNA was isolated using the QIAamp DNA Mini 
Kit (QIAGEN, Hilden, Germany) according to the manu-
facturer’s instructions using frozen brain tissue of the two 
iCJD cases (Case 1 and 2). All primer pairs were designed 
to amplify the coding exons of PSEN1, PSEN2 (preseni-
lin 1, 2), PRNP (prion protein gene) and exon 16 and 17 
of AβPP (Aβ precursor protein) including adjacent exon/
intron boundaries. The PCR fragments were purified by 
agarose gel electrophoresis and sequenced using the Dye 
Terminator cycle sequencing kit (Version 3.1; Applied Bio-
systems, Foster City, CA) with electrophoresis on an ABI 
3130 Genetic Analyzer (Applied Biosystems). To genotype 
APOE, restriction fragment length polymorphism was used 
as described previously [22]. In brief, a fragment within 
exon 4 of the APOE gene was amplified by PCR. Then the 
amplified 244 bp fragment was cut with restriction enzyme 
HhaI. Restriction fragments were separated on a 16 % pol-
yacrylamide gel and visualized.
Results
Description of cases examined
Case iCJD-1 was a 33-year-old woman who had suffered 
a traumatic open right frontobasal skull fracture followed 
by surgical implantation of lyophilized cadaveric dura 
25 years before death. After the operation epileptic seizures 
occurred; the last one 15 years before death. She developed 
progressive dementia at the age of 33 associated with cer-
ebellar ataxia, myoclonus and pyramidal signs. She died 
due to bronchopneumonia after 4 months disease duration. 
CSF 14-3-3 protein was positive and EEG revealed tripha-
sic waves. There was a lack of reports on amnestic or focal 
cortical symptoms before the development of progressive 
neurological symptoms. There was no family history of 
dementia or any other neurological disease.
Case iCJD-2 was a 28-year-old man who had suffered 
a traumatic open left frontobasal skull fracture with brain 
contusion and tearing of the dura mater 22 years before 
death [46]. The dural defect was surgically covered using 
lyophilized cadaveric dura. At the age of 27 he devel-
oped progressive dementia, myoclonus and seizures, later 
pyramidal signs and akinetic mutism. There were no pre-
ceding symptoms. CSF 14-3-3 protein was positive, EEG 
revealed periodic sharp waves, and cranial MRI showed 
discrete hyperintensity of the caudate nucleus and putamen 
in T2 weighted images. Two months before death a diag-
nostic brain biopsy of the left frontal lobe was performed. 
Disease duration was 8 months. There was no family his-
tory of dementia or any other neurological disease.
Genetic analysis of presenilin 2 (PSEN2) revealed 
polymorphic sites at codons 23, 43 and 87 (c.69T>C; 
p.Ala23Ala, c.129C>T; p.Asn43Asn and c.261C>T; 
p.His87His, respectively) in both iCJD patients. These pol-
ymorphisms have been reported as having no pathogenic 
impact. In AβPP exons 16 and 17, presenilin 1 (PSEN1) 
and PRNP no pathogenic mutation was observed in both 
patients. Case iCJD-1 was heterozygous (methionine/
valine) and iCJD-2 was homozygous for methionine at the 
polymorphic codon 129 of PRNP. Both cases carried only 
ε3 alleles (ε3/ε3) in the APOE gene.
Neuropathology of iCJD cases
Histology of both iCJD cases revealed mild to moder-
ate spongiform change associated with prominent gliosis 
and neuronal loss and diffuse/synaptic immunoreactiv-
ity for disease-associated PrP (Fig. 1a–f). There were 
no PrP plaques or kuru type plaques. The pattern was 
compatible with MV/MM type 1 [44]. Immunostaining 
for Aβ revealed parenchymal plaques and CAA in both 
cases (see below). Immunostaining for phosphorylated 
tau (AT8) revealed occasional small neuritic profiles as 
described in different forms of CJD [32, 47]. However, 
there was a complete lack of neurofibrillary tangles, pre-
tangles (including subcortical nuclei), neuropil threads, 
or glial tau immunoreactivity. We did not observe any 
tau immunoreactive dystrophic neurites surrounding Aβ 
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plaques although Bielschowsky silver staining did visual-
ize the mature and immature plaques, but mostly without 
abundant argyrophilic neuritic components (Fig. 1g–i). 
In the HE staining we observed several amyloid cores 
in both cases, showing also birefringence under polar-
ized light in the Congo red staining (Fig. 1j, k). Only 
very rare mature plaques showed weakly stained argy-
rophilic neurites (Fig. 1l, m), which were however AT8 
negative. Immunostaining for ubiquitin revealed neuritic 
profiles around some mature plaques (Fig. 1n, o). In the 
white matter close to the area of the traumatic lesion 
focal AβPP deposits were seen in both cases (Fig. 1p, 
q). In case iCJD-2 there was a mononuclear granuloma-
like inflammation in the area of the brain biopsy in the 
left frontal lobe together with ventriculitis and meningitis 
with mononuclear inflammatory infiltrates, interpreted as 
inflammatory sequel of CSF leakage following the biopsy 
[46]. Microglial reaction, together with macrophages, was 
most prominent in the cortex and white matter close to the 
lesion (Fig. 1r, s), while in other areas mostly the cortex 
showed moderate accumulation of ramified microglia. In 
iCJD-2 microgliosis was much more prominent due to the 
recent inflammation.
Fig. 1  Neuropathology of iCJD cases. Mild to moderate spongiform 
change in the HE staining (a, d) associated with diffuse/synaptic PrP 
immunoreactivity (b, e) and focal tau immunoreactive neuritic pro-
files (c, f indicated by arrows, a representative one is enlarged in right 
upper inset) in case iCJD-1 (a–c) and iCJD-2 (d–f). The same mature 
plaque with a corona in iCJD-2 as seen in immunostaining for Aβ (g), 
Bielschowsky (h), AT8 (i arrows indicate small neuritic profiles as 
seen in CJD cases but not around the mature plaque), HE (j arrow-
head) and Congo staining (k arrowhead indicates the plaque as seen 
under polarized light). Bielschowsky staining (l, m) of two mature 
plaques lacking tau immunoreactivity close to each other in iCJD-
2. Immunostaining for Aβ (n) and ubiquitin (o) in the same cortical 
regions close to the dura transplant in iCJD-1. Immunostaining for 
AβPP in frontal white matter in iCJD-1 (p) and iCJD-2 (q). Immu-
nostaining for HLA-DR (microgliosis) in the frontal cortex (r) and 
white matter (s) in iCJD-1. The bar in image “a” represents 100 μm 
for a–f, r, s; 40 μm for g–m; and 60 μm for n–q
Table 1  Anatomical 
distribution of Aβ deposits in 
the two cases of iatrogenic 
Creutzfeldt-Jakob disease 
(iCJD). Focal Aβ deposits are 
stratified as mature (classic) 
plaques and other (immature 
primitive plaques or compact 
plaques). Diffuse Aβ deposits 
include here only subpial 
deposits. If there was no 
difference between the two 
sides (R: right, L: left) they are 
summarized in one row. Further 
Aβ deposition indicates lake-
like immunoreactivity in the 
lesion area, deposits in a venous 
dilatation (temporal in iCJD-1) 
and amorphous deposits in the 
dura
R right, L left, Fr frontal, Te temporal, Pa parietal, Occ occipital, GGl Ganglia, − indicates negative, +, 
++, +++ indicates positive (mild, moderate, severe, respectively)
a Site of dural grafting in iCD-2
b Site of dural grafting in iCD-1
c Cornu ammonis, subiculum, entorhinal and inferior temporal cortex
d Host dura was examined beside the grafted dura in iCJD-1 and more than 5 cm away from the operation 
site in iCJD-2
Region/Aβ iCJD-1 iCJD-2
CAA Focal Diffuse Further CAA Focal Diffuse Further
Mature Other Mature Other
Frontobasal La − − + − − ++ ++ ++ + −
Frontobasal Rb ++ +++ +++ − +++ + − + − +
Middle Fr L − + + − − ++ ++ ++ − −
Middle Fr R + − + − − + − + − −
Middle-Upper Te L + + + − − + − ++ + −
Middle-Upper Te R + + + − + + − + − −
Inferior Pa R-L − − − − − + + + − −
Occ R-L + − − − − + − + − −
Hippocampusc R-L − − − − − + − − − −
Basal GGl R-L − − − − − − − − − −
Thalamus R-L − − − − − − − − − −
Mesencephalon − − − − − − − − − −
Pons − − − − − − − − − −
Medulla oblongata − − − − − − − − − −
Cerebellum − − − − − − − − − −
Dura graft + − − − + + − − − +
Dura hostd − − − − − − − − − −
◂
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Distribution and morphology of dural and brain Aβ 
deposits in the iCJD cases
Both cases showed similar morphology of Aβ immuno-
reactivities, characterized by CAA (type 2) [51] and pre-
dominantly focal cortical deposits, including cored mature 
plaques, immature primitive plaques and focal cores 
without a surrounding corona. Parenchymal Aβ deposits 
accumulated closer to the area of the operation (Table 1), 
appeared in clusters, and were seen mostly in the frontal 
and temporal cortex. In iCJD-2 we observed mature and 
primitive plaques and focal deposits in the anterior cin-
gulate gyrus on the lesion side; furthermore, occasional 
perivascular focal deposits in the occipital cortex and occa-
sional plaques in the parietal cortex were also observed. 
Accordingly, both cases were classified as phase 1 accord-
ing to Thal et al. [53], with the note that in iCJD-2 the 
involvement of the anterior cingulate suggested phase 2, 
however, the complete lack of parenchymal Aβ deposits 
in the entorhinal cortex, hippocampus, and insular cortex 
deviated from the established phase 2. CAA was seen in 
neocortical areas but not in subcortical areas or cerebel-
lum (stage 1) [52]. There was a lack of dyshoric angiopathy 
or fibrinoid necrosis of vessels. In case iCJD-1 mostly the 
leptomeningeal vessels showed CAA, while in iCJD-2 the 
cortical vasculature additionally exhibited prominent CAA.
In case iCJD-1, the traumatic lesion area where the 
graft was implanted showed prominent tissue damage. Aβ 
showed unusual lake-like appearance in the white matter 
adjacent to the tissue defect, strongly labeled by Aβ1–40 
and Aβ1–42 as well (Fig. 2a–e). Aβ deposits radiated from 
the lesion (Fig. 2f) and included linear and fine granular, 
but not axonal bulb-like Aβ depositions in the perilesional 
white matter (Fig. 2g, h) and at the gray-white matter junc-
tion. In addition, in the adjacent cortical area, columns 
of Aβ deposits, oriented perpendicular to the brain sur-
face, were noted (Fig. 2i–l). In further cortical areas, with 
decreasing density away from the lesion (Table 1), either 
single cores or clusters of plaques, both primitive and 
mature, were seen. CAA involved mostly the meningeal 
vessels including large venous dilatations (Fig. 2m) and the 
cortical arteries were less involved. The plaques and CAA 
were observed using all anti-Aβ antibodies; Aβ1–40 showed 
mostly CAA and the cores of plaques, while Aβ1–42 immu-
nolabeled the corona of the plaques as well (Fig. 2n, o). 
The grafted dura mater also showed amorphous Aβ depo-
sitions including adjacent sinus-like dilatations (Fig. 2p–s).
In case iCJD-2 we observed two focal deposits and a sin-
gle vessel with CAA already in the brain biopsy from the 
frontal cortex. In the post mortem specimens the operated 
area showed prominent inflammatory changes. In addition 
to CAA (Fig. 3a), we observed perivascular focal deposits, 
including cored plaques (Fig. 3b). Subpial diffuse deposits 
were seen only focally in the temporal lobe (Table 1), and 
these also showed mini-cores (Fig. 3c). Furthermore, cor-
tical Aβ deposition showed clustering of plaques, which 
were mostly focal deposits including mature and primitive 
plaques (Fig. 3d). In preserved cortical areas adjacent to the 
lesion we recognized columns of Aβ deposits perpendicular 
to the surface (Fig. 3d). Several samples of dura mater from 
the host (more than 5 cm from the operated area) lacked Aβ 
deposition (Fig. 3e). In contrast, there was amorphous Aβ 
immunoreactivity in the grafted dura (Fig. 3f–i).
In summary, common features comprise (1) amorphous 
Aβ deposits in the grafted but not host dura mater; (2) 
presence of parenchymal deposits (iCJD-1 > iCJD-2) and 
CAA (iCJD-2 > iCJD-1); (3) predominance of focal depos-
its (mature and immature plaques) and lack of ill-defined 
irregular diffuse plaques; (4) predominance of plaques 
in areas close to the traumatic lesion where the graft was 
implanted; (5) clustering of plaques in cortical areas with-
out laminar preference or homogenous involvement of all 
layers; (6) tendency for columnar alignment of focal depos-
its perpendicular to the surface in the vicinity of the lesion; 
and (7) complete lack of neuronal or glial tau pathology 
and particularly of plaque-associated tau-positive dys-
trophic neurites.
Morphology and frequency of dural Aβ deposits  
in the VITA cohort
In the VITA cohort we observed typical morphology of 
CAA with congophilia in 11/84 cases (13.09 %; median 
age: 85 years, range 82–89); and amorphous deposits 
of Aβ in the connective tissue mostly adjacent to dural 
sinuses in 11/84 cases (13.09 %; median age: 86 years, 
range 84–88; only five of these cases with CAA also). 
The age was not significantly different between groups 
showing or lacking Aβ immunoreactivity in the dura. 
Both CAA and the amorphous deposits were detectable 
by the 4G8, 6F/3D, anti-Aβ1–40, and anti-Aβ1–42 anti-
bodies (Fig. 4a–o, r, s). In the connective tissue, where 
we observed amorphous Aβ immunoreactivity, collagen 
IV decorated basement membranes (Fig. 4d, e inset). 
Fig. 2  Aβ immunoreactivity in iCJD-1. Immunostaining using the 
6F/3D Aβ antibody (a, b, f, g, i–m, p–s), the 4G8 Aβ antibody (c, 
h), anti-Aβ1–40 (e, n), and anti-Aβ1–42 (d, o) demonstrated wide-
spread immunoreactivity in the lesion area (a upper part enlarged 
in b–e); radiating deposits in the cortex (f) and white matter (g, h); 
focal deposits with columnar alignment perpendicular to the sur-
face of the cortex (i–l); in a dilated vein (m), as immunostaining of 
plaques (n, o); and as dural deposits (p–s). The right upper inset in 
p is the enlargement of the area indicated by an arrowhead; r and s 
are enlargements of areas indicated by arrow and arrowhead in q, 
respectively. The bar in image “a” represents 150 μm for a, f, l, m–o; 
60 μm for b–e; 40 μm for g, h, j, k; 100 μm for i, p, q and 15 μm 
for r, s
▸
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Combined presence of CAA and amorphous deposits 
was seen only in five cases. Using enhanced protein-
ase K treatment, both types of lesions were detectable 
by both 4G8 and 6F/D3 anti-Aβ antibodies (Fig. 4c, 
t); furthermore, focally they showed birefringence in 
Congo staining under polarized light (Fig. 4p, q). In 
addition, some vessels showed fine granular deposits 
without congophilia, detectable only by the 4G8 anti-
body in the media of arteries, in 41/84 cases (48.8 %; 
median age: 85 years, range 82–89). Detectability of 
these morphologies using anti-Aβ antibodies did not 
correlate with the duration of the formalin fixation of 
samples.
Next we compared the presence of the different mor-
phologies with neuropathological variables including the 
presence of Lewy body pathology, TDP-43 proteinopa-
thy, tauopathy, parenchymal Aβ deposits or CAA in the 
brain or leptomeningeal vessels, vascular lesions in the 
brain and Braak neurofibrillary stage. It is of note that 
cases with the presence of typical CAA detected by all 
antibodies in the examined dura samples showed Aβ 
deposits in the brain (100 %), while 8 (72.7 %) of them 
showed also CAA in the examined brain samples. Simi-
larly, dural amorphous deposits were significantly asso-
ciated with Aβ deposits in the brain (100 %), and in 10 
cases (90.9 %) there was also CAA in the brain and lep-
tomeningeal vessels (p < 0.01 according to χ2 and Fisher 
exact test for both comparisons). In contrast, presence of 
fine granular Aβ immunoreactivity detectable only with 
the 4G8 antibody in the media of large arteries did not 
show correlation with any of these. Furthermore, none 
of the dural Aβ morphologies was associated with tau, 
TDP-43, Lewy body, or vascular pathologies detected in 
the brain.
Fig. 3  Aβ immunoreactivity in iCJD-2. Immunostaining using the 
6F/3D Aβ antibody (a–i) representing cerebral amyloid angiopathy 
(a), perivascular cored plaque (b upper right inset is the enlarged 
image of the vessel below the letter “b”), single area with subpial 
deposits (c including minicored plaques indicated by an arrowhead 
and as enlarged in the right upper inset); columnar alignment of 
plaques in the cortex (d indicated by a row of arrowheads; the sur-
face of the cortex is labeled by a dashed line); lack of immunoreactiv-
ity in the host dura mater (e) and amorphous Aβ depositions in the 
graft dura mater (f–i; h and i is the enlargement of the areas indicated 
by an arrow and arrowhead in g, respectively). The bar in image 
“a” represents 150 μm for a; 40 μm for b, f; 100 μm for c, d, e, g; 
15 μm for h, i
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Fig. 4  Aβ in the dura mater in the aging brain. Image a–m repre-
sents dura mater samples from a representative patient as visualized 
by 4G8 (a–c; in c using enhanced PK treatment of the sections), 
6F/3D Aβ antibody (d–g; insets in d and e represent immunostaining 
for collagen IV; f and g are enlargements of the areas indicated by 
asterisk in d and e, respectively), Aβ1–40 (h, j), Aβ1–42 (i, k) and van 
Gieson elastica (l, m). Further representative cases are shown using 
immunostaining for Aβ1–40 (n), Aβ1–42 (o), Congo staining under 
polarized light (p deposit in the connective tissue, q angiopathy), and 
6F/3D (r–t; areas indicated with asterisk enlarged in the right upper 
inset; in t using enhanced PK-pretreatment). The bar in image “a” 
represents 20 μm for c, f, g, n, p, q, t; 40 μm for a, b, d, e, o, r, and 
s; and 80 μm for h–m
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Discussion
To contribute to the emerging issue of potential transmis-
sibility of neurodegenerative conditions and related pro-
teins we re-evaluated two iCJD cases in which the grafted 
dura mater was available. In addition, we addressed the 
question whether Aβ can deposit in the dura mater in aged 
individuals.
Comparison of Aβ pathology with sporadic AD 
and TBI‑related neurodegeneration
In sporadic AD, deposits of Aβ are classified as diffuse, 
stellate and focal [14]. Diffuse deposits are poorly immu-
noreactive and their borders are ill-defined. Depending on 
the localization they show lake-like or fleecy morphology 
or they appear as subpial bands. Focal deposits are dif-
ferent and they are further stratified whether they have a 
neuritic corona or not [2, 14]. Importantly, a grading sys-
tem was suggested for these lesions, beginning with purely 
focal Aβ deposition, followed by appearance of Congo 
red positive material with neurites and variable degree 
of ubiquitination, which later show immunoreactivity for 
hyperphosphorylated tau, and finally associate with neu-
rofibrillary tangles in the vicinity of plaques [42]. Impor-
tantly, diffuse Aβ deposits are considered as the earliest 
form, while mature plaques can be seen later [14, 15]. 
Another important aspect of Aβ pathology is the hierar-
chical and stereotypical involvement of different brain 
regions, which follows five distinct phases [53]; the neo-
cortex is involved in the first phase. Moreover, the study 
by Cupidi et al. suggested considerable heterogeneity of 
neocortical Aβ deposition in late phases of AD [12]. That 
study identified two patterns: a laminar intracortical pat-
tern and another one where the six isocortical layers were 
homogeneously involved [12]. Further studies showed that 
diffuse and focal deposits distinctly appear in different 
layers of the cortex [13], which was not seen in our cases. 
Indeed, the two iCJD cases examined here revealed a dis-
tinct pattern. On one hand there was neither an unequivo-
cal laminar pattern nor homogenous involvement of corti-
cal layers even in regions with many mature and primitive 
plaques. Aβ deposition frequently appeared in clusters 
away from the lesion site or showed columnar alignment 
close to the lesion. On the other hand, the maturation pro-
cess of plaques [42] was not recognizable; neither diffuse 
Aβ deposits with ill-defined borders, nor any tau immu-
noreactivities in the corona of mature plaques were seen. 
Thus, in spite of the presence of mature plaques, only 
grade 2 (out of 4 as proposed by Metsaars et al [42].) of 
isocortical Alzheimer lesions could be recognized. There-
fore, we conclude that the Aβ deposition seen in our iCJD 
cases is distinct from that seen in AD. It must be noted that 
Αβ immunoreactivity frequently appears in certain forms 
of genetic CJD (e.g. E200K mutation) even in younger 
patients [19, 35]; furthermore, young individuals without 
cognitive decline may have Αβ deposits in the neocortex 
[45]. Importantly, these are also different from that seen 
in the present iCJD cases, since they are predominated by 
irregular diffuse plaques with ill-defined border lacking 
amyloid cores. Moreover, in young individuals the pres-
ence of the ε4 allele of the APOE gene is significantly 
associated with the appearance of Aβ plaques [44]. Our 
iCJD cases, representing the youngest cases where Aβ 
deposits were observed in iCJD [18, 25], carried only ε3 
allele in the APOE gene; furthermore, there was a lack of 
pathogenic mutations in genes associated with altered Aβ 
metabolism (i.e. AβPP, PSEN1, PSEN2). It is important to 
emphasize that apart from the sparse small neuritic profiles 
detected in all prion disease types [32, 35, 47], we did not 
observe neuronal tau pathology in subcortical neuronal 
groups [7, 8, 20, 50] or thread like profiles [33] as reported 
in young individuals.
A possible explanation for the increased frequency of 
Aβ pathology in our iCJD cases might be simply the effect 
of brain trauma. Recent studies indicate that following 
repetitive injury CTE develops, which pathognomistically 
shows tau pathology [39], although Aβ deposition can be 
additionally seen [40, 41]. In our patients there was neither 
repeated trauma documented nor were any clinical symp-
toms or tau pathologies compatible with CTE observed. 
Another form of neurodegeneration has been documented 
in individuals many years after a single TBI, showing Aβ 
but also tau deposition [28]. We also observed chronic 
lesions, such as accentuated microgliosis and macrophages 
and occasional axonal bulbs, which may persist years 
after TBI as described by Johnson and colleagues [26]. 
In contrast, TBI cases were reportedly less likely to dis-
play smaller clustered regions of plaques and more likely 
to have widespread plaques across the entire cortex [28]. 
Together with the lack of tau pathology in the iCJD cases 
examined, the distribution of plaques has to be emphasized: 
it showed higher density close to the dura mater graft. 
Interestingly, another study on TBI did not find Aβ plaques 
in long-term survivors suggesting regression with time 
[11]. In short-term survivors of acute TBI mostly Aβ1–42 
immunoreactivity was seen as non-neuritic plaques [23]. A 
recent study using the amyloid tracer 11C-Pittsburgh com-
pound B to evaluate amyloid pathology in vivo in individu-
als with a history of TBI (11 months to 17 years) demon-
strated a distinct involvement of the cerebellum [49] unlike 
in our patients. Importantly, the images showed no binding 
in the vicinity of focal cortical lesions in TBI evident on 
structural MRI [49], which also contrasts with our iCJD 
cases where most of the amyloid pathology was in cortical 
regions close to the graft. Finally, ε4 carriers of the APOE 
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gene have been discussed to be at increased risk for devel-
oping Aβ pathology after TBI [27].
Interestingly, CAA is less emphasized in TBI. Less than 
10 % frequency has been reported in individuals with TBI 
shortly after the injury, mostly associated with the presence 
of the APOE ε4 allele [36]. CAA was seen in the brain in 
ex-boxers [54]. In sporadic CAA the pathogenesis includes 
altered clearance or increased production of Aβ [52]. In the 
present iCJD cases CAA was observed only in the leptome-
ninges and in the neocortex (stage 1). It might be theorized 
that the grafted dura containing Aβ deposits impaired the 
physiological clearance facilitated by additional seeding of 
Aβ to the vessels. Interestingly, perivascular Aβ deposits 
frequently showed cores (Fig. 3b), which is unusual in AD.
In summary, the pathology seen in the two iCJD cases 
was distinct not only from AD brains but also from that 
described in long-term survivors of TBI or in CTE. The 
observation of Aβ deposits in the grafted but not in the host 
dura mater suggests a scenario of seeding of the pathologi-
cal protein to the underlying CNS. However, the Aβ seeds 
alone seem to be inefficient in reproducing the complete 
clinicopathological phenotype of AD. Lack of the clini-
cal phenotype of AD has been emphasized in recipients of 
cadaveric human growth hormone [24]. This contrasts with 
prion diseases, where the seeding of disease-associated PrP 
leads to widespread involvement of the brain together with 
the entire phenotype.
Dural Aβ pathology in the aging brain
Next we addressed the question how frequently and in what 
form does Aβ pathology involve the dura mater in aging. In 
spite the small size of the dura sample examined (4 cm2) 
we were able to detect deposits associated with AD type 
pathology in the CNS. CAA and amorphous deposits were 
labeled by all antibodies even following harsh PK-pretreat-
ment of sections and showed birefringence in Congo red 
staining using polarized light. These morphologies were 
similar to that seen in the grafted dura samples in iCJD 
cases. The fine granular immunoreactivity detectable only 
with antibody 4G8 in the media of vessels showed no spe-
cific correlation with neuropathological variables and was 
not interpreted as CAA, in particular since antibody 4G8 
also detects intracellular AβPP [1].
It was suggested that amyloid proteins have a ubiqui-
tous affinity to basement membranes [6] as demonstrated 
for dura-related Aβ deposits in our study and also by 
Keable and colleagues [29]. Indeed, amyloid deposits in 
the dura mater (pachymeninx), but not in the leptomenin-
ges, have been shown in cases with generalized (systemic) 
amyloidosis, which on the other hand involve CNS tis-
sue usually only in regions where the blood brain barrier 
is not sufficient [6]. In contrast, cerebral Aβ amyloidosis 
predominantly affects CNS tissue and vessels in the CNS 
and leptomeninges [6]. Here we expand the spectrum of 
tissues showing Aβ deposition in cerebral Aβ amyloidosis 
by demonstrating that the dura mater indeed accumulates 
pathological Aβ without selectivity for Aβ1–40 or Aβ1–42 in 
the amorphous deposits. It has long been suggested that the 
dura mater is a metabolically inert, avascular, fibrous cov-
ering of the brain. However, the dura mater also contains 
basal membranes [3], including in the abundant micro-
vascularization, which is not commensurate with the role 
previously attributed to the dura mater [48]. Many studies 
have suggested that CAA is a protein elimination failure 
angiopathy where CAA reflects impaired perivascular lym-
phatic drainage (for reviews see [5, 10, 57]). Until recently, 
however, the lymphatic system of the dura mater received 
less attention. Early studies already emphasized that the 
lymphatic system might play a role in the fluid circulation 
of the brain [17, 30]. Interestingly, recent studies confirmed 
that a lymphatic system lining the dural sinuses drains the 
brain interstitial fluid [4, 38], which might have relevance 
to understand our observation of the accumulation of amor-
phous Aβ deposits in the vicinity of dural sinuses in a 
cohort of elderly individuals.
Conclusions
We provide novel observations complementing a recent 
study on the increased frequency of Aβ pathology in iCJD 
associated with dura mater transplantation [18]. The pat-
tern of Aβ deposition together with the lack of accompa-
nying tau pathology differentiates the Aβ proteinopathy in 
iCJD from sporadic and genetic forms of AD; from that 
seen in young individuals without cognitive decline carry-
ing one or two APOE4 alleles; from that in young genetic 
CJD patients with mutation in the PRNP gene; and from 
that related to TBI and CTE. Additionally, the presence 
of Aβ in the grafted but not the host dura mater suggests 
that we observe here an example of ‘infectious propagon’ 
[15]. Infectious propagons have been defined as “proteins 
that transmit pathological conformation between individu-
als” [15]. However, of significance is the lack of clinical 
symptoms reminiscent of AD and of the full neuropatho-
logical picture of AD, which contrast with the phenotype-
reproducing property of prions in prion diseases. In fact, 
we demonstrate here that pathological Aβ protein, rather 
than AD, can be propagated between humans. Therefore, 
we propose to distinguish Aβ as an ‘infectious propagon’ 
(when only the pathological conformation is transmit-
ted between individuals) from disease-associated PrP as a 
‘phenotype propagon’ (when the pathological conformation 
of the protein and the full clinicopathological phenotype is 
transmitted between individuals; e.g. prion disease). This 
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concept would also help to better understand reports on 
horizontal transmission of other amyloids like the AA amy-
loid in captive cheetahs [43]. In addition, our observations 
in a cohort of elderly individuals show that the dura mater 
does not infrequently harbor Aβ, especially in the vicin-
ity of sinuses, which provides an important aspect to the 
understanding of the drainage of this protein from the CNS.
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